Posted by Michael Wonder on 01 Nov 2022
First immunotherapy for patients with a potentially life threatening type of non-melanoma skin cancer now available on the PBS
1 November 2022 - Australians with a potentially life-threatening type of non-melanoma skin cancer will for the first time, have access to subsidised immunotherapy when it becomes available on the Pharmaceutical Benefits Scheme on 1 November.
Libtayo (cemiplimab) will be PBS funded for adults with metastatic or locally advanced cutaneous squamous cell carcinoma when curative surgery and curative radiation is not suitable.
